Lisocabtagene Maraleucel PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Autologous CD4-positive and CD8-positive T cells are genetically modified to express an anti-CD19 chimeric antigen receptor containing 4-1BB costimulatory and CD3-zeta signalling domains. After infusion, the cells recognise CD19-expressing B-lineage tumour cells and mediate T-cell activation, proliferation and cytotoxic killing.
Indications / reported uses
Treatment of adults with specified large B-cell lymphomas, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B, in the treatment settings defined by the current product label.
The current US label includes selected earlier-line and later-line settings; primary central nervous system lymphoma is not an indicated use.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Lisocabtagene Maraleucel PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Lisocabtagene Maraleucel Permitted Daily Exposure (PDE) report (the Lisocabtagene Maraleucel PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Lisocabtagene Maraleucel Occupational Exposure Limit (OEL) report (the Lisocabtagene Maraleucel OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.